Asarfi Hospital's 500-bed target is now 2028. Its margin ceiling is lower too.
The company's FY27 guidance for ₹250-260 cr revenue still looks ambitious. But the long-term profitability target was cut without explanation.
What's new
- FY26 revenue hit ₹173.5 cr, up 42% year-on-year, with PAT up 58% to ₹15.7 cr.
- FY27 revenue guidance is ₹250-260 cr, a 50% jump from the just-completed year.
- Cancer hospital revenue grew 65% to ₹33 cr but is only at 42% occupancy on a 65-bed base.
Themes from the call
Growth
The core thesis is a rapid ramp at the cancer hospital, which needs to deliver the bulk of the 50% FY27 revenue growth target alongside an inorganic acquisition.
Margins
FY26 EBITDA margin was 20%, but the FY27 guidance band is 22-25%, while the long-term terminal margin was quietly cut to 23-25%.
Execution
The bone marrow facility is delayed 4-5 months pending a government policy, and the hospital merger is not yet closed, leaving key growth pillars in limbo.
Guidance watch
- FY27 guidance: ₹250-260 cr revenue, 22-25% EBITDA margin, 13-15% PAT margin.
- Vision 2028: 500+ beds, ₹400 cr revenue, with the long-term EBITDA margin target cut from 25-27% to 23-25%.
- Capex guidance for FY27 is less than ₹15 cr, with ₹8-10 cr earmarked for a Health Management Research Institute.
Risk flags
- The Vision 2028 margin ceiling of 23-25% is 200 bps lower than the 25-27% guided in November 2025, and management did not explain why.
- The 500-bed timeline has slipped a year without any formal acknowledgement, raising questions about execution pace.
- Ayushman Bharat delivers only 15% of cancer hospital revenue at low package rates, and slow 6-7 month reimbursement cycles create cash flow risk.
Key quotes
-
"Looking ahead, we remain focused on our vision for 2027, expanding total bed capacity to 500..."
— Harendra Singh, Asarfi Hospital, Nov 2025 call -
"Our Vision 2028 roadmap targets scaling overall bed capacity to 500 plus beds..."
— Harendra Singh, Asarfi Hospital, May 2026 call
The brief
Asarfi Hospital delivered a strong FY26, with revenue up 42% to ₹173.5 cr and PAT up 58% to ₹15.7 cr. The cancer hospital business grew 65% to ₹33 cr and remains the engine for a further 50% jump in FY27 to ₹250-260 cr. These are the numbers the market is being asked to trust.
The trust exercise is complicated by two quiet reversals. In November 2025, management spoke of a 2027 target for 500 beds. That is now a 2028 target. In the same November call, the long-term EBITDA margin guidance was 25-27%. It is now 23-25%. Neither change was explained on the May call.
The operational risks are real and specific. The bone marrow transplant unit is delayed 4-5 months waiting on a Jharkhand government policy. The promised inorganic acquisition, which is supposed to contribute meaningfully to the ₹250-260 cr FY27 target, is 'almost settled' but not closed. And Ayushman Bharat, which generates only 15% of cancer hospital revenue, comes with low reimbursement rates and 6-7 month payment cycles.
The FY26 execution was clean. The FY27 plan is a 50% growth target that requires both the cancer hospital to scale fast and an acquisition to close on time. Management is guiding for 22-25% EBITDA margins in FY27 while telling investors the long-term ceiling is the same band. That is a tight target with no room for the government policy delays or working capital elongation it is simultaneously flagging.
Asarfi's growth story is intact, but its credibility got a little cheaper this quarter.